8-K: Walgreens Boots Alliance Files Supplemental Merger Disclosures Amid Shareholder Lawsuits

Walgreens Boots Alliance, Inc. has filed an 8-K to provide supplemental disclosures to its definitive proxy statement, addressing shareholder lawsuits and demand letters challenging the proposed merger with Blazing Star Parent, LLC.

Summary

• Walgreens Boots Alliance, Inc. (WBA) filed an 8-K to supplement its definitive proxy statement on Schedule 14A, originally filed on June 6, 2025, concerning the proposed merger with Blazing Star Parent, LLC.
• The supplemental disclosures address two shareholder lawsuits, Drulias v. Babiak, et al. and Johnson v. Walgreens Boots Alliance, Inc., et al., filed on June 16, 2025, and June 18, 2025, respectively.
• These lawsuits, along with 11 demand letters, generally allege that the definitive proxy statement misrepresents or omits material information regarding financial projections, financial advisor conflicts of interest, and the merger process.
• WBA denies the claims but is voluntarily providing these supplemental disclosures to moot the plaintiffs' claims and avoid potential expenses and business delays.
• The amendments include restatements of sections on the 'Background of the Merger' and 'Opinion of the Financial Advisors to the Board,' providing additional details on board discussions, financial advisor relationships, and valuation methodologies.
• Updated financial projections (February, October, and December Projections, and VMD Forecasts) are included, detailing estimated revenues, Adjusted EBITDA, Adjusted Operating Income, Unlevered Free Cash Flow, and Free Cash Flow through fiscal year 2029 or calendar year 2030.
• The Company Special Meeting for stockholders to vote on the Merger Agreement is scheduled for July 11, 2025.

Sentiment

Score: 4

Explanation: The document is primarily a legal disclosure addressing shareholder lawsuits and demand letters related to a merger. While the company denies the claims, the existence of such legal challenges and the need for supplemental disclosures indicate a negative development. The financial projections also highlight challenges like insufficient free cash flow to cover dividends and declining operating income, contributing to a cautious sentiment.

Positives

• The company believes the claims asserted in the Merger Actions and Demand Letters are without merit.
• WBA is voluntarily providing supplemental disclosures to avoid nuisance, potential expense, and business delays, rather than admitting legal merit or necessity.
• The Board concluded that the relationships of financial advisors, Centerview and Morgan Stanley, would not affect their ability to serve the company.

Negatives

• Two shareholder lawsuits (Drulias Action and Johnson Action) have been filed, alleging misrepresentations and omissions in the definitive proxy statement related to financial projections, conflicts of interest, and the merger process.
• Eleven demand letters have been received from purported stockholders seeking additional disclosures in the definitive proxy statement.
• The lawsuits generally seek to enjoin the stockholder vote on the Merger Agreement and the consummation of the Merger unless additional information is disclosed.
• October Management Projections indicated that the company's expected free cash flow would be insufficient to cover the historical $1.00 per share dividend in fiscal years 2025 through 2029.
• The company has experienced a decline in adjusted operating income and free cash flow since 2022 due to headwinds in its U.S. retail pharmacy and healthcare businesses.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Affiliates of Sycamore Partners may not obtain the necessary financing arrangements set forth in commitment letters.
• Failure to satisfy any of the conditions to the consummation of the proposed transaction, including regulatory and stockholder approvals.
• The occurrence of any event, change, or circumstance that could give rise to the termination of the transaction agreements, potentially requiring the company to pay a termination fee.
• The announcement or pendency of the proposed transaction could negatively affect the company's business relationships, operating results, and business generally.
• The proposed transaction may disrupt the company's current plans and operations.
• The company's ability to retain and hire key personnel and maintain relationships with key business partners and customers may be impacted.
• Management's attention may be diverted from ongoing business operations due to the proposed transaction.
• Significant or unexpected costs, charges, or expenses may result from the proposed transaction.
• Potential litigation relating to the proposed transaction could be instituted against the parties or their directors, managers, or officers, with uncertain outcomes.
• Uncertainties exist regarding the continued availability of capital and financing and potential rating agency actions.
• Certain restrictions during the pendency of the proposed transaction may impact the company's ability to pursue business opportunities or strategic transactions.
• Uncertainty exists as to the timing of completion of the proposed transaction.
• Holders of Divested Asset Proceed Rights may receive less-than-anticipated payments or no payments, and such rights may expire valueless.
• Adverse general and industry-specific economic and market conditions could impact the company.
• There is a possibility that alternative transaction proposals will or will not be made.
• The company's stock price may decline significantly if the merger is not completed.
• The possibility of a leak of transaction discussions could lead to Sycamore stopping its proposal and significant disruption to relationships with employees, business counterparties, and other stakeholders.

Future Outlook

The company's financial projections extend through fiscal year 2029 (and 2030 for VMD Group), reflecting management's assumptions on retail sales trends, debt refinancing, cost optimization, store closures, prescription reimbursement pressures, opioid payment obligations, and asset monetization activities. The October Management Projections indicated that the company's expected free cash flow would be insufficient to cover the historical $1.00 per share dividend in fiscal years 2025-2029, suggesting potential future adjustments to dividend policy or financial performance.

Management Comments

• The company believes the claims asserted in the Merger Actions and the Demand Letters are without merit but cannot predict the outcome of such claims.
• While the company believes that the disclosures set forth in the Definitive Proxy Statement fully comply with all applicable laws and denies all of the allegations set forth in the pending Merger Actions, it has determined to voluntarily supplement certain disclosures to moot plaintiffs' disclosure claims and avoid nuisance, potential expense, and business delays.
• Mr. Pessina confirmed to the Board that, should the Board determine a transaction with Sycamore would be in the best interests of all stockholders, he would consider taking any reasonable action necessary to facilitate such transaction, including rolling over all or part of his equity interests, and would not condition his support of any transaction on his ability to participate.

Industry Context

The document highlights that the company's U.S. retail pharmacy and healthcare businesses face headwinds, including prescription reimbursement pressures and the impact of its footprint optimization program (store closures). It notes the uniqueness of the company's U.S. retail business in the public market, which makes sum-of-the-parts analysis challenging and suggests limited interest from other financial sponsors or strategic counterparties for a transaction of this size due to the required funds, varied business mix, and potential regulatory considerations.

Comparison to Industry Standards

• Centerview's Selected Public Company Analysis compared WBA to US Retail companies (e.g., Albertsons, CVS, Target, Kroger) and International Retail companies (e.g., Tesco, Marks and Spencer), observing a mean EV/NTM EBITDA Trading Multiple of 5.9x across the total peer group, with US Retail averaging 6.8x and International Retail averaging 4.8x. Centerview applied a reference range of 5.0x to 7.0x to WBA's estimated NTM Adjusted EBITDA.
• Centerview's Select Precedent Transaction Analysis reviewed transactions involving U.S. Grocery (e.g., Whole Foods Market, Supervalu Inc.) and North America General Retail companies (e.g., Nordstrom, Staples, Belk), with a total median TEV/LTM EBITDA Multiple of 6.9x. Centerview selected a reference range of 5.5x to 7.5x for WBA.
• Morgan Stanley's Public Trading Comparables Analysis assessed WBA against companies like CVS Health, other US Retailers (e.g., Kroger, Dollar General), International retailers (e.g., Ulta Beauty, Tesco), and Distributors (e.g., McKesson, Cencora), calculating implied CY2025E P/E multiples and noting the Implied Consideration Value of $12.64 to $13.36 per share relative to the implied per share values of $7.95 to $12.25 from this analysis.

Corporate Governance

Legal Proceedings

• Drulias v. Babiak, et al., No. 2025CH00000145, filed on June 16, 2025, in the Circuit Court for Lake County, Illinois. This lawsuit alleges violations of the Illinois Securities Act of 1953, negligent misrepresentation, concealment, and negligence under Illinois law.
• Johnson v. Walgreens Boots Alliance, Inc., et al., C.A. No. 653635/2025, filed on June 18, 2025, in the Supreme Court of the State of New York, County of New York. This lawsuit alleges negligent misrepresentation and concealment, and negligence in violation of New York common law.
• Both 'Merger Actions' generally allege that the Definitive Proxy Statement misrepresents and/or omits certain purportedly material information relating to financial projections and analyses performed by the company's financial advisors, alleged conflicts of interest, and the Merger process.
• The Merger Actions generally seek, among other things, to enjoin the vote of Company stockholders to adopt the Merger Agreement and the consummation of the Merger unless and until certain additional information is disclosed, as well as costs including plaintiffs' attorneys' and experts' fees.
• The company has received 11 demand letters from purported stockholders seeking additional disclosures in the Definitive Proxy Statement.
• The company believes the claims asserted in the Merger Actions and the Demand Letters are without merit but cannot predict the outcome of such claims.
• Additional lawsuits and demand letters arising out of the Merger may also be filed or received in the future, which the company may not disclose absent new or significantly different allegations.

Related Party Transactions

• Mr. Pessina, a significant existing stockholder, confirmed to the Board that, should the Board determine a transaction with Sycamore would be in the best interests of all stockholders, he would consider rolling over all or part of his equity interests to facilitate such transaction. He reiterated that he would only engage in discussions with Sycamore about a potential rollover of his equity interests with the Board's full knowledge and approval, and that he would not condition his support of any transaction on his ability to participate.

Stakeholder Impact

• Shareholders: Directly impacted by the proposed merger, the ongoing lawsuits challenging the adequacy of information provided for their vote, and the potential for delays or termination of the transaction. The lawsuits specifically target the information shareholders rely on for their decision.
• Employees, Business Counterparties, and Other Stakeholders: Face a significant risk of disruption to their relationships with the company if transaction discussions leak or if the merger process is prolonged or ultimately terminated, potentially affecting morale, operations, and business continuity.
• Creditors: Affected by the company's financial health, including its estimated net debt of $6.818 billion and capital lease liability of $980 million. The outcome of the merger and its associated financing arrangements could influence the company's credit profile and ability to service its obligations.

Next Steps

• The Company Special Meeting is scheduled for July 11, 2025, for stockholders to vote to adopt the Merger Agreement.
• Additional lawsuits and demand letters arising out of the Merger may be filed or received in the future, though the company may not disclose them absent new or significantly different allegations.

Key Dates

Keywords

Walgreens Boots Alliance, WBA, SEC filing, 8-K, merger, acquisition, proxy statement, shareholder lawsuit, litigation, financial projections, corporate governance, Sycamore Partners, retail pharmacy, healthcare, financial analysis, risk management